This program is supported by an independent education grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

Join us for a live online course in collaboration with the Human Growth Foundation, presented by leading experts Prof Bradley Miller, Prof Sasigarn Bowden & Prof Kevin Yuen. Learn the latest advances in the diagnosis and management of Growth Hormone Deficiency (GHD) in both pediatric and adult patients, including LAGH therapy. By participating in this program, you will gain a deeper understanding of emerging clinical guidelines, diagnostic tools, and therapeutic approaches.

Accreditation: 1.5 AMA PRA Category 1 Credits™ will be available for this education

KeyTopics :

Accurate Diagnosis: Learn to effectively evaluate patients with suspected GHD, integrating clinical presentation, laboratory findings, and genetic testing.
Optimizing Treatment Selection including LAGH therapy: Gain expertise in selecting appropriate treatment options, including daily GH and long-acting GH (LAGH) therapy, based on individual patient needs.
Manage the transition from pediatric to adult care: Hone your skills in monitoring and adjusting GH therapy to achieve optimal long term outcomes, including strategies for improving adherence and minimizing side effects.
Data-Driven Decision Making: Learn to interpret IGF-I levels and other biomarkers to guide treatment decisions and monitor patient response.

Professor Kevin Yuen

Kevin Yuen, MD, is a neuroendocrinologist and medical director of the Barrow Pituitary Center and Barrow Neuroendocrinology Clinic. He also serves as a professor in the Department of Neurology at Barrow Neurological Institute. Board-certified in internal medicine and endocrinology, Dr. Yuen specializes in managing pituitary and adrenal disorders, including growth hormone imbalances, cortisol abnormalities, and hypogonadism. His research focuses on pituitary function, particularly in growth hormone studies, and he is recognized globally for his contributions.

Professor Sasigarn Bowden

Sasigarn Bowden, MD, is a pediatric endocrinologist at Nationwide Children's Hospital and a clinical professor of pediatrics at The Ohio State University College of Medicine. She earned her medical degree from Chiang Mai University in Thailand, followed by pediatric training at Prince of Songkla University and the University of Tennessee. Dr. Bowden completed a fellowship in pediatric endocrinology at Cincinnati Children’s Hospital. Board-certified in pediatrics and pediatric endocrinology, her clinical and research focus includes metabolic bone disorders, pediatric osteoporosis, growth, and diabetes. She also serves as associate program director for the fellowship program and contributes to educational and clinical initiatives at Nationwide Children's Hospital.

Professor Bradley Miller

Dr. Miller is a Pediatric Endocrinologist and Professor of Pediatric Endocrinology at the University of Minnesota. His clinical and research interests focus on the growth hormone/insulin-like growth factor system and its role in typical and atypical growth in children. He also studies growth and development in children affected by cancer treatments, fetal alcohol exposure, and international adoption. Additionally, Dr. Miller is involved in research on endocrine issues in congenital glycosylation disorders and skeletal dysplasias, including achondroplasia.

Human Growth Foundation

The Human Growth Foundation (HGF), a non-profit organization founded in 1965, serves as a global leader in endocrine research, education, patient advocacy, and support. It is dedicated to improving the lives of individuals affected by growth and bone conditions. HGF supports research, educates families and healthcare providers, and raises public awareness about these conditions. Their vision is to empower children and adults with growth disorders to reach their full potential by providing comprehensive support, promoting early diagnosis and treatment, and fostering a community of understanding.

Who Should Attend:

Endocrinologists
Pediatric Endocrinologists
Primary Care Physicians
Pediatricians
Internal Medicine Physicians
Nurse Practitioners
Physician Assistants
Pharmacists
Pediatric Nurse Specialists

Continuing Education Information

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Faculty

Prof Bradley Miller, Prof Sasigarn Bowden & Prof Kevin Yuen

Disclosures

Kevin Yuen is an Advisory Board Member for Novo Nordisk, Ascendis, Chiesi and Crinetics. His institution has received research grants from Ascendis and Novo Nordisk. He He is an occasional speaker for Novo Nordisk. He has no unapproved product related discussions to disclose.

Sasigarn Bowden is and Advisory Board member for Alexion & Pfizer. Her institution has received research funding from Lumos. He has no unapproved product related discussions to disclose.

Dr. Miller is a consultant for Amgen, Ascendis Pharma, BioMarin, Eton Pharmaceuticals, Novo Nordisk, Pfizer, Soleno and Tolmar and has received research support from Alexion, Abbvie, Aeterna Zentaris, Ascendis Pharma, Foresee, Lumos Pharma, Novo Nordisk, OPKO Health, and Pfizer. He has no unapproved product related discussions to disclose.

AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and Medall. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Physician Assistants

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity will be planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE will designate this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs

There is no cost to participate in this program.

Learning objectives

Evaluate patients with suspected GHD by integrating clinical presentation, laboratory findings, and genetic testing:

Differentiate GHD from other conditions with similar symptoms to ensure accurate and timely diagnosis in both pediatric and adult patients.
Utilize appropriate diagnostic tests and interpret the results in the context of each patient’s clinical profile. Collaborate with specialists, when needed, to confirm the diagnosis and streamline the referral process for comprehensive care.

Select appropriate candidates for transitioning from daily GH therapy to LAGH based on clinical criteria and patient needs:

Assess patient adherence challenges, comorbidities, and treatment goals to determine suitability for LAGH.
Effectively communicate with patients and caregivers to set realistic expectations and improve long-term adherence to LAGH therapy.
Monitor and adjust LAGH therapy in line with individual patient responses to optimize outcomes.

Implement individualized IGF-I monitoring strategies to optimize therapy for patients receiving daily GH or LAGH:

Interpret fluctuations in IGF-I levels to make data-driven decisions on dosing and therapy adjustments.
Tailor monitoring approaches based on the pharmacokinetic and pharmacodynamic differences between daily GH and LAGH therapies.
Apply long-term surveillance data to ensure patient safety, efficacy, and adherence during treatment

View all